Skip to main content

Table 1 Study design and patient population

From: Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data

Study Inclusion criteria Patients contributing data to pooled analysis, n
Age, years HbA1c, % eGFR, mL/min/1.73 m2 PBO CANA
100 mg
CANA
300 mg
Total
Monotherapy 18–80 7.0–10.0 ≥50 192 195 197 584
Add-on to MET 18–80 7.0–10.5 ≥55 183 368 367 918
Add-on to MET + SU 18–80 7.0–10.5 ≥55 156 157 156 469
Add-on to MET + PIO 18–80 7.0–10.5 ≥55 115 113 114 342
Overall total, N     646 833 834 2313
  1. Data have been previously reported [19, 22, 24]
  2. eGFR estimated glomerular filtration rate, PBO placebo, CANA canagliflozin, MET metformin, SU sulphonylurea, PIO pioglitazone